m+Medelevator.RU
← Поиск публикаций
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2009

Effect of hydrogen peroxide of bacterial origin on apoptosis and necrosis of gut mucosa epithelial cells as a possible pathomechanism of inflammatory bowel disease and cancer.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Strus M, Janczyk A, Gonet-Surowka A, Brzychczy-Wloch M, Stochel G, Kochan P, Heczko P B

Аннотация

A series of in vitro experiments was arranged to assess effects of different concentrations of H(2)O(2) contained in bacterial cultures on apoptosis and necrosis of HT-29 line cells representing human gut epithelium. On the basis of cytofluorimetric assays it was possible to demonstrate that supernatant of the Lactobacillus strain producing hydrogen peroxide (L. delbrueckii CU/22) was able to induce both apoptosis and necrosis in human epithelial culture cells HT-29. Both effects were more prominent than those visible under influence of supernatant of the non-H(2)O(2)-producing Lactobacillus strain or chemically pure H(2)O(2) at the same concentration used as a control. In the light of this study and also other reports on damaging effects of hydrogen peroxide and superoxide radicals of bacterial origin on colonic cells, commensal bacteria of the human gut producing H(2)O(2) may be involved in pathomechanisms of IBD by perpetuating the inflammatory reaction and increasing apoptosis and necrosis. There is a promise that probiotic preparations containing Lactobacillus bacteria will be successful as adjunct therapy of IBD and it is, therefore, postulated to make a very careful selection of the Lactobacillus strains as candidates for probiotics indicated to ameliorate the course of IBD, before starting clinical trials.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты